2. Search Result
Search Result
Results for "

CK2 Inhibitor

" in MedChemExpress (MCE) Product Catalog:

55

Inhibitors & Agonists

5

Natural
Products

2

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-15535
    DMAT
    5 Publications Verification

    CK2 Inhibitor; Casein kinase II Inhibitor

    		 Casein Kinase Cancer
    DMAT is a potent and specific CK2 inhibitor with an IC50 value of 130 nM.
    DMAT
  • HY-132175
    CK2 inhibitor 2

    		Casein Kinase Cancer
    CK2 inhibitor 2 is a potent, selective and orally active inhibitor of CK2, with an IC50 of 0.66 nM. CK2 inhibitor 2 shows high selectivity for Clk2 (IC50=32.69 nM)/CK2. CK2 inhibitor 2 exhibits favorable antiproliferative and antitumor activity .
    CK2 inhibitor 2
  • HY-143461
    CK2 inhibitor 3

    		Casein Kinase Cancer
    CK2 inhibitor 3 is a potent CK2 inhibitor with IC50 value of 280 nM. CK2 inhibitor 3 inhibits endocellular CK2, significantly affects viability of tumour cells and shows remarkable selectivity on a panel of 320 kinases .
    CK2 inhibitor 3
  • HY-155987
    CK2-IN-8

    		Casein Kinase Cancer
    CK2-IN-8 (compound 5c) is a CK2 inhibitor with IC50 >33 μM .
    CK2-IN-8
  • HY-12570
    CK2-IN-9

    		Casein Kinase Wnt Cancer
    CK2-IN-9 is a potent and selective inhibitor of CK2 kinase with an IC50 of 3 nM. CK2-IN-9 reduces Wnt reporter activity with an IC50 of 75 nM. CK2-IN-9 has low exposure (AUC=0.36 μM/h) and high clearance (CL=65 mL/min/kg) properties in rat .
    CK2-IN-9
  • HY-153788
    CK2-IN-7

    		Casein Kinase Cancer
    CK2-IN-7 (compound 2) is an inhibitor of casein kinase 2 (CK2). CK2-IN-7 shows synergistic effect with structurally distinct CK2 chemical probe: SGC-CK2-1, against cancer .
    CK2-IN-7
  • HY-121792
    CK2-IN-1

    		Casein Kinase Others
    CK2-IN-1 is a CK2 inhibitor, with an IC50 of 150 nM .
    CK2-IN-1
  • HY-169985
    CK2-IN-13

    		Casein Kinase Cancer
    CK2-IN-13 (compound 12c) is a potent inhibitor of CK2, with the IC50 of 5.8 nM. CK2-IN-13 plays an important role in cancer research .
    CK2-IN-13
  • HY-158369
    CK2-IN-10

    		Others Cancer
    CK2-IN-10 (31), an allosteric CK2 inhibitor, can be used in the research of cancer .
    CK2-IN-10
  • HY-151382
    CK2-IN-3

    		Casein Kinase Cancer
    CK2-IN-3 is a selective and potent CK2 inhibitor (Kd: 12 nM), with IC50 values of 1.51 μM (CK2α) and 7.64 μM (CK2α’). CK2-IN-3 can be used in the research of cancers .
    CK2-IN-3
  • HY-118403
    CK2-IN-12

    		Casein Kinase Infection Inflammation/Immunology Cancer
    CK2-IN-12 (Compound 39) is an inhibitor for protein kinase CK2 with an IC50 of 0.8 μM .
    CK2-IN-12
  • HY-168517
    PIM-1/CK2-IN-2

    		Pim Casein Kinase Apoptosis Cancer
    PIM-1/CK2-IN-2 (compound 3aA) is a PIM-1/CK2 inhibitor. PIM-1/CK2-IN-2 can induce the mitochondrial apoptotic pathway in CCRF-CEM cells. PIM-1/CK2-IN-2 can be used in cancer research .
    PIM-1/CK2-IN-2
  • HY-148328
    CK2-IN-4

    		Casein Kinase Infection Inflammation/Immunology Cancer
    CK2-IN-4 (compound 5) is a protein kinase (CK2) inhibitor (IC50=8.6 µM). CK2-IN-4 has good potential for research in the areas of cancer, viral infections and glomerulonephritis .
    CK2-IN-4
  • HY-158370
    CK2-IN-11

    		Others Cancer
    CK2-IN-11 (32) is an allosteric CK2 inhibitor, with high selectivity for CK2 with IC50 values of 19.3 nM and 15.6 nM for the CK2α2β2 and the CK2α′2β2 isoforms, respectively .
    CK2-IN-11
  • HY-14394
    TBB
    10+ Cited Publications

    NSC 231634; Casein Kinase II Inhibitor I

    		 Casein Kinase Cancer
    TBB is a cell-permeable and ATP-competitive CK2 inhibitor with an IC50 of 0.15 μM for rat liver CK2.
    TBB
  • HY-145260
    BRD4/CK2-IN-1

    		Epigenetic Reader Domain Casein Kinase Apoptosis Autophagy Cancer
    BRD4/CK2-IN-1 is the first highly effective and oral active dual-target inhibitor of BRD4/CK2 (bromodomain-containing protein 4/casein kinase 2), with IC50s of 180 nM and 230 nM for BRD4 and CK2, respectively. BRD4/CK2-IN-1 has strong anticancer activity without obvious toxicities. BRD4/CK2-IN-1 induces apoptosis and autophagy-associated cell death in triple-negative breast cancer (TNBC)
    BRD4/CK2-IN-1
  • HY-135816
    CK2/PIM1-IN-1

    		Casein Kinase Pim Inflammation/Immunology Cancer
    CK2/PIM1-IN-1 is an inhibitor of CK2 and PIM1, with IC50s of 3.787 μM and 4.327 μM for CK2 and PIM1, respectively. CK2/PIM1-IN-1 is developed for the research of proliferative disorders such as cancer, as well as other kinase-associated conditions including inflammation, pain, vascular disorders, pathogenic infections and certain immunological disorders .
    CK2/PIM1-IN-1
  • HY-148763
    CK2-IN-6

    		Casein Kinase Inflammation/Immunology Cancer
    CK2-IN-6 is a potent protein kinase CK2 inhibitor that can be used in the study of cancer as well as other kinase-related conditions, including inflammation, pain and certain immune diseases .
    CK2-IN-6
  • HY-103384
    TMCB

    		Casein Kinase Cancer
    TMCB is a selective, ATP-competitive CK2 (casein kinase II) inhibitor with distinct Ki values of 83 nM and 21 nM for the two different catalytic CK2 subunits α and α', respectively .
    TMCB
  • HY-135906
    CK2/ERK8-IN-1

    		Casein Kinase ERK Pim DYRK Apoptosis Cancer
    CK2/ERK8-IN-1 is a dual casein kinase 2 (CK2) (Ki of 0.25 µM) and ERK8 (MAPK15, ERK7) inhibitor with IC50s of 0.50 μM. CK2/ERK8-IN-1 also binds to PIM1, HIPK2 (homeodomain-interacting protein kinase 2), and DYRK1A with Kis of 8.65 µM, 15.25 µM, and 11.9 µM, respectively. CK2/ERK8-IN-1 has pro-apoptotic efficacy .
    CK2/ERK8-IN-1
  • HY-168707
    CK2-IN-14

    		Casein Kinase Cancer
    CK2-IN-14 (Compound 10b) is an inhibitor for cyclin kinase 2α with an IC50 of 36.7 nM. CK2-IN-14 inhibits the growth of cancer cell 786-O and U937 with GI50 of 7.3 μM and 7.5 μM .
    CK2-IN-14
  • HY-110052
    TBCA

    		Casein Kinase Cancer
    TBCA is a highly selective CK2 (casein kinase II) inhibitor with an IC50 of 110 nM and a Ki of 77 nM. TBCA shows selectivity for CK2 over CK1, DYRK1A and a panel of 27 other kinases .
    TBCA
  • HY-108606
    PI-828
    1 Publications Verification

    		 PI3K Casein Kinase Cancer
    PI-828 is a dual PI3K and casein kinase 2 (CK2) inhibitor with IC50s of 173 nM, 149 nM, and 1127 nM for p110α, CK2, and CK2α2 in lipid kinase assay, respectively .
    PI-828
  • HY-15479
    TTP 22
    2 Publications Verification

    		 Casein Kinase Inflammation/Immunology Cancer
    TTP 22 is a potent CK2 inhibitor, with an IC50 of 100 nM and a Ki of 40 nM.
    TTP 22
  • HY-158371
    HDAC/CK2-IN-1

    		HDAC Casein Kinase Cancer
    HDAC/CK2-IN-1 (compound 38) is a HDAC1 (IC50 = 1.46 μM), HDAC6 (IC50 = 0.66 μM), and CK2 (IC50 = 3.67 μM) inhibitor. HDAC/CK2-IN-1 exhibits promising antproliferative activity against Jurkat, MCF-7, HCT-116, and HL-60 cell lines .
    HDAC/CK2-IN-1
  • HY-50855B
    Silmitasertib sodium salt
    35+ Cited Publications

    CX-4945 sodium salt

    		 Casein Kinase Autophagy Cancer
    Silmitasertib sodium salt is an orally bioavailable, highly selective and potent CK2 inhibitor, with IC50 values of 1 nM against CK2α and CK2α'.
    Silmitasertib sodium salt
  • HY-50855
    Silmitasertib
    35+ Cited Publications

    CX-4945

    		 Casein Kinase Autophagy Cancer
    Silmitasertib (CX-4945) is an orally bioavailable, highly selective and potent CK2 inhibitor, with IC50 values of 1 nM against CK2α and CK2α'.
    Silmitasertib
  • HY-117332
    IQA

    CGP-029482

    		 Casein Kinase Cancer
    IQA (CGP-029482) is a potent and selective protein kinase CK2 inhibitor .
    IQA
  • HY-B0183A
    Ellagic acid (hydrate)

    		Casein Kinase Cancer
    Ellagic acid hydrate is a natural antioxidant, and acts as a potent and ATP-competitive CK2 inhibitor, with an IC50 of 40 nM and a Ki of 20 nM .
    Ellagic acid (hydrate)
  • HY-B0183
    Ellagic acid
    10+ Cited Publications

    		 Casein Kinase Reactive Oxygen Species Endogenous Metabolite SHP2 Neurological Disease Cancer
    Ellagic acid is a natural antioxidant, and acts as a potent and ATP-competitive inhibitor of CK2 and SHP2, with an IC50 of 40 nM and a Ki of 20 nM.
    Ellagic acid
  • HY-W042648
    4,5,6,7-Tetrabromo-1H-benzimidazole

    		Casein Kinase Others
    4,5,6,7-Tetrabromobenzimidazole is a selective and ATP competitive CK2 (casein kinase 2) inhibitor .
    4,5,6,7-Tetrabromo-1H-benzimidazole
  • HY-120267
    TID43

    		Casein Kinase Cardiovascular Disease
    TID43 is a CK2 inhibitor, with an IC50 of 0.3 μM. TID43 can be used for anti-angiogenic research .
    TID43
  • HY-124833
    Quinalizarin

    		Casein Kinase Cancer
    Quinalizarin is a potent, selective and cell-permeable protein kinase CK2 inhibitor with an Ki of ~50 nM and an IC50 of 110 nM. Quinalizarin can induce apoptosis of certain cancer cells .
    Quinalizarin
  • HY-50733A
    CX-5011

    		Casein Kinase Ras Apoptosis Cancer
    CX-5011 is a CK2 inhibitor. CX-5011 also induces Rac1 activation. CX-5011 induces apoptosis and induces cancer cell death .
    CX-5011
  • HY-B0183R
    Ellagic acid (Standard)

    		Casein Kinase Reactive Oxygen Species Endogenous Metabolite SHP2 Neurological Disease Cancer
    Ellagic acid (Standard) is the analytical standard of Ellagic acid. This product is intended for research and analytical applications. Ellagic acid is a natural antioxidant, and acts as a potent and ATP-competitive inhibitor of CK2 and SHP2, with an IC50 of 40 nM and a Ki of 20 nM.
    Ellagic acid (Standard)
  • HY-15260
    XL413
    4 Publications Verification

    BMS-863233

    		 CDK Cancer
    XL413 is a potent, selective and ATP competitive inhibitor of Cdc7, with an IC50 of 3.4 nM, and also shows potent effect with IC50s of 215, 42 nM on CK2, PIM1, respectively, and an EC50 of 118 nM on pMCM.
    XL413
  • HY-B0183S
    Ellagic acid-13C12

    		Isotope-Labeled Compounds Others
    Ellagic acid- 13C12 is 13 C-labeled Ellagic acid (HY-B0183). Ellagic acid is a natural antioxidant and acts as a potent and ATP-competitive inhibitor of CK2 and SHP2, with an IC50 of 40 nM and a Ki of 20 nM .
    Ellagic acid-13C12
  • HY-15260A
    XL413 monohydrochloride
    4 Publications Verification

    BMS-863233 monohydrochloride

    		 CDK Cancer
    XL413 (BMS-863233) hydrochloride is a potent, selective and ATP competitive inhibitor of Cdc7, with an IC50 of 3.4 nM, and also shows potent effect with IC50s of 215, 42 nM on CK2, PIM1, respectively, and an EC50 of 118 nM on pMCM.
    XL413 monohydrochloride
  • HY-114653
    SRPIN803

    		Casein Kinase SRPK Cancer
    SRPIN803 is a potent CK2 and SRPK1 dual inhibitor, with IC50s of 203 nM and 2.4 μM, respectively. SRPIN803 exhibits antiangiogenic activity. SRPIN803 can be used for the research of age-related macular degeneration .
    SRPIN803
  • HY-162078
    Antiproliferative agent-46

    		Casein Kinase Cancer
    Antiproliferative agent-46 (compound 5e) is an inhibitor of the casein kinase-2 enzyme (CK2) receptor. Antiproliferative agent-46 has a potent antiproliferative activity with an IC50 value of 5.75 μM on the U87 cell line .
    Antiproliferative agent-46
  • HY-156816
    ON 108600

    		Casein Kinase DYRK Cancer
    ON 108600 is a inhibitor for CK2 (Casein Kinase2)/TNIK/DYRK1 , with the IC50s for DYRK1A/DYRKB, DYRK2, CK2α1/CK2α2, and TNIK of 0.016 μm/0.007 μM, 0.028 μM, 0.05 μM/0.005 μM, and 0.005 μM, respectively. ON 108600 has antitumor activity .
    ON 108600
  • HY-115519
    (E/Z)-GO289
    1 Publications Verification

    		 Casein Kinase Cancer
    (E/Z)-GO289 is a potent and selective casein kinase 2 (CK2) inhibitor (IC50=7 nM). (E/Z)-GO289 strongly lengthens circadian period. (E/Z)-GO289 exhibits cell type–dependent inhibition of cancer cell growth that correlated with cellular clock function .
    (E/Z)-GO289
  • HY-10108A
    LY294002 hydrochloride
    Maximum Cited Publications
    792 Publications Verification

    		 PI3K Casein Kinase DNA-PK Apoptosis Cancer
    LY294002 hydrochloride is a potent and broad-spectrum PI3K inhibitor, with IC50 values of 0.5, 0.57, and 0.97 μM for P110α, P110δ and P110β, respectively. LY294002 hydrochloride also inhibits CK2 with an IC50 of 98 nM. LY294002 hydrochloride can be used for pancreatic cancer research .
    LY294002 hydrochloride
  • HY-50733
    CX-5011 free base

    		Apoptosis Casein Kinase Ras Cancer
    CX-5011 free base is a potent CK2 inhibitor. CX-5011 free base also is a Rac-1 activator. CX-5011 free base induces methuosis and promotes macropinocytosis. CX-5011 free base induces apoptosis. CX-5011 free base decreases the expression of rpS6 phosphorylation .
    CX-5011 free base
  • HY-15424
    5-Iodotubercidin
    5+ Cited Publications

    NSC 113939; 5-ITu

    		 Adenosine Kinase Cancer
    5-Iodotubercidin (NSC 113939), an ATP mimetic, is a potent adenosine kinase inhibitor with an IC50 of 26 nM. 5-Iodotubercidin (NSC 113939) initiates glycogen synthesis in isolated hepatocytes by causing inactivation of phosphorylase and activation of glycogen synthase. 5-Iodotubercidin (NSC 113939) also inhibits CK1, insulin receptor tyrosine kinase, phosphorylase kinase, PKA, CK2, PKC and Haspin .
    5-Iodotubercidin
  • HY-124321
    Metralindole hydrochloride

    		Others Cancer
    Metralindole hydrochloride is a significant inhibitor of human cyclin-dependent kinase-2 and Human Protein Kinase CK2 Holoenzyme, exhibiting high binding affinity in the context of lung cancer treatment. Metralindole hydrochloride demonstrates promising docking scores and molecular dynamics stability, indicating its potential efficacy as a therapeutic agent against non-small cell lung cancer. Metralindole hydrochloride further shows excellent pharmacokinetic properties, including outstanding solubility and bioavailability, making it a compelling candidate for future experimental validation in lung cancer therapy.
    Metralindole hydrochloride
  • HY-10108
    LY294002
    Maximum Cited Publications
    792 Publications Verification

    		 PI3K Casein Kinase DNA-PK Apoptosis Autophagy Infection Cancer
    LY294002 is a broad-spectrum inhibitor of PI3K with IC50s of 0.5, 0.57, and 0.97 μM for PI3Kα, PI3Kδ and PI3Kβ, respectively . LY294002 also inhibits CK2 with an IC50 of 98 nM . LY294002 is a competitive DNA-PK inhibitor that binds reversibly to the kinase domain of DNA-PK with an IC50 of 1.4?μM. LY294002 is an apoptosis activator .
    LY294002
  • HY-14393
    Emodin
    20+ Cited Publications

    Frangula emodin

    		 SARS-CoV Casein Kinase Autophagy 11β-HSD Cancer
    Emodin (Frangula emodin), an anthraquinone derivative, is an anti-SARS-CoV compound. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 (ACE2) interaction . Emodin inhibits casein kinase-2 (CK2). Anti-inflammatory and anticancer effects . Emodin is a potent selective 11β-HSD1 inhibitor with the IC50 of 186 and 86 nM for human and mouse 11β-HSD1, respectively. Emodin ameliorates metabolic disorder in diet-induced obese mice .
    Emodin
  • HY-14393S
    Emodin-d4

    Frangula emodin-d4

    		 Isotope-Labeled Compounds SARS-CoV Casein Kinase Autophagy 11β-HSD Cancer
    Emodin-d4 is the deuterium labeled Emodin. Emodin (Frangula emodin), an anthraquinone derivative, is an anti-SARS-CoV compound. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 (ACE2) interaction[1]. Emodin inhibits casein kinase-2 (CK2). Anti-inflammatory and anticancer effects[2]. Emodin is a potent selective 11β-HSD1 inhibitor with the IC50 of 186 and 86 nM for human and mouse 11β-HSD1, respectively. Emodin ameliorates metabolic disorder in diet-induced obese mice[3].
    Emodin-d4
  • HY-14393R
    Emodin (Standard)

    Frangula emodin (Standard)

    		 SARS-CoV Casein Kinase Autophagy 11β-HSD Cancer
    Emodin (Standard) is the analytical standard of Emodin. This product is intended for research and analytical applications. Emodin (Frangula emodin), an anthraquinone derivative, is an anti-SARS-CoV compound. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 (ACE2) interaction . Emodin inhibits casein kinase-2 (CK2). Anti-inflammatory and anticancer effects . Emodin is a potent selective 11β-HSD1 inhibitor with the IC50 of 186 and 86 nM for human and mouse 11β-HSD1, respectively. Emodin ameliorates metabolic disorder in diet-induced obese mice .
    Emodin (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: